D. Boral Capital Reaffirms Buy Rating for Omeros (NASDAQ:OMER)

D. Boral Capital reissued their buy rating on shares of Omeros (NASDAQ:OMER) in a research report report published on Friday morning,Benzinga reports. The firm currently has a $36.00 price objective on the biopharmaceutical company’s stock.

OMER has been the subject of several other research reports. Needham & Company LLC restated a “hold” rating on shares of Omeros in a report on Friday, January 17th. StockNews.com cut shares of Omeros from a “hold” rating to a “sell” rating in a report on Friday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $22.50.

Omeros Stock Performance

Shares of Omeros stock opened at $9.10 on Friday. The company has a fifty day simple moving average of $8.70 and a 200-day simple moving average of $7.37. Omeros has a 12-month low of $2.61 and a 12-month high of $13.60. The stock has a market cap of $527.35 million, a price-to-earnings ratio of -3.94 and a beta of 2.03.

Institutional Trading of Omeros

Several institutional investors and hedge funds have recently bought and sold shares of the business. Two Sigma Investments LP raised its position in Omeros by 8.8% in the 4th quarter. Two Sigma Investments LP now owns 162,991 shares of the biopharmaceutical company’s stock valued at $1,610,000 after purchasing an additional 13,201 shares during the last quarter. ProShare Advisors LLC raised its position in Omeros by 75.0% in the 4th quarter. ProShare Advisors LLC now owns 18,496 shares of the biopharmaceutical company’s stock valued at $183,000 after purchasing an additional 7,927 shares during the last quarter. Nomura Holdings Inc. raised its position in Omeros by 136.2% in the 4th quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company’s stock valued at $7,383,000 after purchasing an additional 430,932 shares during the last quarter. Millennium Management LLC raised its position in Omeros by 46.2% in the 4th quarter. Millennium Management LLC now owns 85,671 shares of the biopharmaceutical company’s stock valued at $846,000 after purchasing an additional 27,088 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Omeros by 3.6% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,831 shares of the biopharmaceutical company’s stock worth $314,000 after buying an additional 1,110 shares during the last quarter. Hedge funds and other institutional investors own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.